| 1 |
33549596 | Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression. | 2021 Apr 15 |
2 |
| 2 |
33629325 | Zinc oxide nanoparticles promotes liver cancer cell apoptosis through inducing autophagy and promoting p53. | 2021 Feb |
1 |
| 3 |
33667419 | Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. | 2021 Jun |
1 |
| 4 |
32218859 | Potential synergistic effects of sorafenib and CP-31398 for treating anaplastic thyroid cancer with p53 mutations. | 2020 Apr |
4 |
| 5 |
32373219 | Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. | 2020 |
1 |
| 6 |
32382022 | Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. | 2020 May 7 |
2 |
| 7 |
29870655 | Rattle-Structured Rough Nanocapsules with in-Situ-Formed Gold Nanorod Cores for Complementary Gene/Chemo/Photothermal Therapy. | 2018 Jun 26 |
1 |
| 8 |
30033448 | Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response. | 2018 Aug |
2 |
| 9 |
28350084 | TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. | 2017 Apr |
1 |
| 10 |
28476378 | Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. | 2017 Jun |
1 |
| 11 |
28781658 | Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. | 2017 Aug |
2 |
| 12 |
27965580 | OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53. | 2016 |
2 |
| 13 |
25196217 | BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation. | 2015 Mar 15 |
1 |
| 14 |
25557114 | Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. | 2015 Feb |
5 |
| 15 |
25738310 | Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2. | 2015 |
1 |
| 16 |
22006587 | Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. | 2013 Jan |
7 |
| 17 |
22096025 | Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. | 2012 Jan 1 |
1 |
| 18 |
22678405 | The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines. | 2012 |
2 |
| 19 |
22689683 | The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. | 2012 Nov |
2 |
| 20 |
21725213 | Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. | 2011 Aug 1 |
1 |
| 21 |
21929745 | Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. | 2011 Sep 19 |
4 |
| 22 |
19777160 | Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. | 2010 Dec |
1 |